1-20 of 20
Allen C. Gao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Available to Purchase
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (10): 1594–1607.
https://doi.org/10.1158/1535-7163.MCT-22-0216
Published: 07 October 2022
View articletitled, Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
Open the PDF for Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment in another window
Includes: Supplementary data
Journal Articles

Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer

Free
Alan P. Lombard, Cameron M. Armstrong, Leandro S. D'Abronzo, Shu Ning, Amy R. Leslie, Masuda Sharifi, Wei Lou, Christopher P. Evans, Marc Dall'Era, Hong-Wu Chen, Xinbin Chen, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 677–685.
https://doi.org/10.1158/1535-7163.MCT-21-0604
Published: 01 April 2022
View articletitled, Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer
Open the PDF for Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer in another window
Journal Articles

Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells

Available to Purchase
Alan P. Lombard, Wei Lou, Cameron M. Armstrong, Leandro S. D'Abronzo, Shu Ning, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 2061–2070.
https://doi.org/10.1158/1535-7163.MCT-20-0983
Published: 01 October 2021
View articletitled, Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells
Open the PDF for Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Free
Jinge Zhao, Shu Ning, Wei Lou, Joy C. Yang, Cameron M. Armstrong, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao, Chengfei Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (8): 1708–1718.
https://doi.org/10.1158/1535-7163.MCT-20-0015
Published: 04 August 2020
View articletitled, Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
Open the PDF for Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer in another window
Journal Articles

Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs

Available to Purchase
Yongqiang Wang, Zenghong Huang, Christopher Z. Chen, Chengfei Liu, Christopher P. Evans, Allen C. Gao, Fangjian Zhou, Hong-Wu Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-19-0327
Published: 06 February 2020
View articletitled, Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs
Open the PDF for Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs in another window
Includes: Supplementary data
Journal Articles

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Free
Chengfei Liu, Joy C. Yang, Cameron M. Armstrong, Wei Lou, Liangren Liu, Xiaomin Qiu, Binhao Zou, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1875–1886.
https://doi.org/10.1158/1535-7163.MCT-18-1322
Published: 01 October 2019
View articletitled, AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
Open the PDF for AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression

Free
Vito Cucchiara, Joy C. Yang, Chengfei Liu, Hans H. Adomat, Emma S. Tomlinson Guns, Martin E. Gleave, Allen C. Gao, Christopher P. Evans
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1811–1821.
https://doi.org/10.1158/1535-7163.MCT-18-1337
Published: 01 October 2019
View articletitled, GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression
Open the PDF for GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression in another window
Includes: Supplementary data
Journal Articles

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Free
Alan P. Lombard, Liangren Liu, Vito Cucchiara, Chengfei Liu, Cameron M. Armstrong, Ruining Zhao, Joy C. Yang, Wei Lou, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (10): 2197–2205.
https://doi.org/10.1158/1535-7163.MCT-17-1269
Published: 01 October 2018
View articletitled, Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer
Open the PDF for Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer in another window
Journal Articles

Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells

Free
Ramakumar Tummala, Wei Lou, Allen C. Gao, Nagalakshmi Nadiminty
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2770–2779.
https://doi.org/10.1158/1535-7163.MCT-17-0030
Published: 03 December 2017
View articletitled, Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
Open the PDF for Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells in another window
Includes: Supplementary data
Journal Articles

ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer

Free
Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10): 2257–2266.
https://doi.org/10.1158/1535-7163.MCT-17-0179
Published: 02 October 2017
View articletitled, ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer
Open the PDF for ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer in another window
Journal Articles

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Free
Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan P. Lombard, Vito Cucchiara, Xinwei Gu, Joy C. Yang, Nagalakshmi Nadiminty, Chong-xian Pan, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (8): 1521–1530.
https://doi.org/10.1158/1535-7163.MCT-16-0912
Published: 02 August 2017
View articletitled, Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
Open the PDF for Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer

Free
Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan Lombard, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (1): 35–44.
https://doi.org/10.1158/1535-7163.MCT-16-0186
Published: 05 January 2017
View articletitled, Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
Open the PDF for Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer in another window
Journal Articles

NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer

Free
Nagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, Wei Lou, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1884–1895.
https://doi.org/10.1158/1535-7163.MCT-14-1057
Published: 05 August 2015
View articletitled, NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Open the PDF for NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer

Free
Yezi Zhu, Chengfei Liu, Nagalakshmi Nadiminty, Wei Lou, Ramakumar Tummala, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (9): 1829–1836.
https://doi.org/10.1158/1535-7163.MCT-13-0208
Published: 05 September 2013
View articletitled, Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Open the PDF for Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants

Free
Nagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, Joy Yang, Wei Lou, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (8): 1629–1637.
https://doi.org/10.1158/1535-7163.MCT-13-0027
Published: 08 August 2013
View articletitled, NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Open the PDF for NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants in another window
Includes: Supplementary data
Journal Articles

Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model

Free
Joy C. Yang, Lanfang Bai, Stanley Yap, Allen C. Gao, Hsing-Jien Kung, Christopher P. Evans
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1629–1637.
https://doi.org/10.1158/1535-7163.MCT-09-1058
Published: 09 June 2010
View articletitled, Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model
Open the PDF for Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model in another window
Journal Articles

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

Free
Siting Feng, Qizhu Tang, Meng Sun, Jae Yeon Chun, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (3): 665–671.
https://doi.org/10.1158/1535-7163.MCT-08-0823
Published: 13 March 2009
View articletitled, Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
Open the PDF for Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 in another window
Journal Articles

Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter

Free
Jae Yeon Chun, Yan Hu, Elaine Pinder, Jianguo Wu, Fengzhi Li, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (9): 2572–2580.
https://doi.org/10.1158/1535-7163.MCT-07-0172
Published: 17 September 2007
View articletitled, Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter
Open the PDF for Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter in another window
Journal Articles

Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer

Free
Jae Yeon Chun, Nagalakshmi Nadiminty, Soo Ok Lee, Sergio A. Onate, Wei Lou, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 913–918.
https://doi.org/10.1158/1535-7163.MCT-05-0389
Published: 28 April 2006
View articletitled, Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer
Open the PDF for Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer in another window
Journal Articles

Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers

Free
Yan Dong, Haitao Zhang, Allen C. Gao, James R. Marshall, Clement Ip
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (7): 1047–1055.
https://doi.org/10.1158/1535-7163.MCT-05-0124
Published: 14 July 2005
View articletitled, Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
Open the PDF for Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers in another window